2-(4-Isopropyl-[1,4]diazepan-1-yl)-ethanol | 59039-63-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂卓
• 英文名称: 2-(4-Isopropyl-[1,4]diazepan-1-yl)-ethanol
• 英文别名: Hexahydro-4-(1-methylethyl)-1H-1,4-diazepine-1-ethanol；2-(4-propan-2-yl-1,4-diazepan-1-yl)ethanol
• CAS: 59039-63-3
• 化学式: C₁₀H₂₂N₂O
• 分子量: 186.297
• InChiKey: NIGIFASRTADART-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(4-Isopropyl-[1,4]diazepan-1-yl)-ethanol 、 4-氯苯氧基乙酰氯 以69%的产率得到
  参考文献：
  名称：

  SZADOWSKA, A.;MAZUR, M.;GRACZYK, J.;KIELEK, M. B.;GURYN, R.;MIKOLAJEWSKA,+, ACTA POL. PHARM., 1982, 39, N 5-6, 361-372

  摘要：

  DOI：
• 作为产物：
  描述：

  2-(2-Isopropylamino-ethylamino)-ethanol 、 1,3-二溴丙烷 以42%的产率得到
  参考文献：
  名称：

  GURYN R.; KOTELKO A.; MAJCHRZAK M., ACTA. POL. PHARM. , 1975, 32, NO 3, 293-301

  摘要：

  DOI：

文献信息

• MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF
  申请人：Weinstein David S.

  公开号：US20090075995A1

  公开（公告）日：2009-03-19

  Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity, including inflammatory and immune diseases, having the structure of formula (I): an enantiomer, diastereomer, or tautomer thereof, or a prodrug ester thereof, or a pharmaceutically-acceptable salt thereof, in which: Z is heterocyclo or heteroaryl; A is a 5- to 8-membered carbocyclic ring or a 5- to 8-membered heterocyclic ring; B is a cycloalkyl, cycloalkenyl, aryl, heterocyclo, or heteroaryl ring, wherein each ring is fused to the A ring on adjacent atoms and optionally substituted by one to four groups which are the same or different and are independently selected from R 5 , R 6 , R 7 , and R 8 ; J 1 , J 2 , and J 3 are at each occurrence the same or different and are independently -A 1 QA 2 -; Q is a bond, O, S, S(O), or S(O) 2 ; A 1 and A 2 are the same or different and are at each occurrence independently selected from a bond, C 1-3 alkylene, substituted C 1-3 alkylene, C 2-4 alkenylene, and substituted C 2-4 alkenylene, provided that A 1 and A 2 are chosen so that ring A is a 5- to 8-membered carbocyclic or heterocyclic ring; R 1 to R 11 are as defined herein. Also provided are pharmaceutical compositions and methods of treating inflammatory- or immune-associated diseases and obesity and diabetes employing said compounds.

  提供了一系列新颖的非甾体化合物，这些化合物在治疗与糖皮质激素受体、AP-1和/或NF-κB活性调节相关的疾病中很有用，包括炎性和免疫疾病，具有以下结构式（I）： 其对应的光学异构体、对映异构体或互变异构体，或其前药酯，或其药用可接受盐，其中： Z是杂环或杂芳基； A是一个5至8成员的碳环或一个5至8成员的杂环； B是一个环烷基、环烯基、芳基、杂环或杂芳基环，其中每个环都与A环上的相邻原子融合，并且可以选择性地被一个到四个独立选自R5、R6、R7和R8的相同或不同的组取代； J1、J2和J3每次出现时相同或不同，独立地选自-A1QA2-；Q是键、O、S、S(O)或S(O)2；A1和A2相同或不同，每次出现时独立地选自键、C1-3烷基、取代的C1-3烷基、C2-4烯基和取代的C2-4烯基，前提是A1和A2的选择使得环A是一个5至8成员的碳环或杂环； R1至R11如本文所述定义。 还提供了使用这些化合物的药物组合物和治疗炎性疾病、免疫相关疾病、肥胖和糖尿病的方法。
• PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Endo Pharmaceuticals Inc.

  公开号：US20140221315A1

  公开（公告）日：2014-08-07

  The present application provides novel pyrimido-pyridazinone compounds and methods for preparing and using these compounds. These compounds are useful in treating inflammation in patients by administering one or more of the compounds to a patient. In one embodiment, the novel pyrimido-pyridazinone compound is of Formula (I) and R 1 and R 2 are defined herein.

  本申请提供了新型嘧啶并吡啶嗪酮化合物以及制备和使用这些化合物的方法。通过向患者投药一种或多种化合物，这些化合物可用于治疗患者的炎症。在一种实施方式中，新型嘧啶并吡啶嗪酮化合物为公式（I）中的化合物，其中R1和R2在此定义。
• Pyrimido-pyridazinone compounds and methods of use thereof
  申请人：Asana Biosciences, LLC

  公开号：US10183944B2

  公开（公告）日：2019-01-22

  The present application provides novel pyrimido-pyridazinone compounds and methods for preparing and using these compounds. These compounds are useful in treating inflammation in patients by administering one or more of the compounds to a patient. In one embodiment, the novel pyrimido-pyridazinone compound is of Formula (I) and R1 and R2 are defined herein.

  本申请提供了新型嘧啶哒嗪酮化合物以及制备和使用这些化合物的方法。通过向患者施用一种或多种化合物，这些化合物可用于治疗患者的炎症。在一个实施方案中，新型嘧啶基哒嗪酮化合物为式(I)，R1和R2在此定义。
• Uses of pyrimido-pyridazinones to treat cancer
  申请人：Asana Biosciences, LLC

  公开号：US10188654B2

  公开（公告）日：2019-01-29

  Disclosed are methods of treating cancer, which include administering a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt or ester thereof, to a subject in need thereof. Also disclosed are methods of inhibiting growth and proliferation of cancer cells in vitro or in vivo, which include contacting the cells with an amount of the compound of formula (I) effective to inhibit the growth or proliferation of the cancer cells. Further disclosed are methods of inhibiting tumor growth, which include contacting the tumor with an amount of the compound of formula (I) effective to inhibit the growth of the tumor.

  所公开的是治疗癌症的方法，其中包括向有需要的受试者施用治疗有效量的式（I）化合物或其药学上可接受的盐或酯。 还公开了体外或体内抑制癌细胞生长和增殖的方法，其中包括使细胞与有效量的式 (I) 化合物接触，以抑制癌细胞的生长或增殖。还公开了抑制肿瘤生长的方法，其中包括使肿瘤与有效抑制肿瘤生长的一定量的式 (I) 化合物接触。
• 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF
  申请人：Genentech, Inc.

  公开号：US20170145020A1

  公开（公告）日：2017-05-25

  Compounds of Formula (00A) and methods of use as Janus kinase inhibitors are described herein.